文献类型：期刊文献

中文题名：化纤保肝方治疗气滞血瘀型肝纤维化的临床研究

英文题名：Clinical Study on HuaQian BaoGan Prescription in the Treatment for Hepatic Fibrosis of Qi Staganation and Blood Stasis Pattern

作者：于立友[1];汪龙德[1];张晶[1];刘俊宏[1]

第一作者：于立友

机构：[1]甘肃中医学院附属医院,甘肃兰州730020

第一机构：甘肃中医药大学第二附属医院

年份：2013

卷号：26

期号：10

起止页码：84

中文期刊名：西部中医药

外文期刊名：Western Journal of Traditional Chinese Medicine

收录：CSTPCD

基金：兰州市科技计划项目(编号2011-2-40)

语种：中文

中文关键词：肝纤维化;化纤保肝方;气滞血瘀;临床研究

外文关键词：hepatic fibrosis; HuaQian BaoGan Prescription; Qi staganation and blood stasis pattern;clinical study

摘要：目的:观察化纤保肝方治疗气滞血瘀型肝纤维化的疗效。方法:将45例肝纤维化患者随机分为治疗组17例,对照组16例,空白组12例。空白组给予基础保肝治疗:口服硫普罗宁片0.1 g/次,3次/d;治疗组在基础治疗基础上加用化纤保肝方(胶囊剂),4粒/次,3次/d;对照组在此基础上加用扶正化瘀胶囊,5粒/次,3次/d,3组均以治疗12周为1个疗程。1个疗程后观察3组患者治疗前后症状评分的变化,肝功能、肝纤4项、血清转化生长因子β_1(TGF-β_1)、血小板衍生生长因子(PDGF)、肿瘤坏死因子α(TNF-α)等基因表达以及瞬时弹性检测仪检测的Fibroscan值的变化。结果:治疗组在改善肝纤维化患者的症状、恢复肝功能、降低肝纤4项指标,抑制TGF-β_1、PDGF、TNF-α等基因的表达、降低Fibroscan值方面明显优于空白组(P<0.05),与对照组比较,差异无统计学意义(P>0.05),但明显优于空白组。结论:化纤保肝方具有很好的抗肝纤维化作用。
Objective： To verify clinical effects of HuaQion BaoGan prescription for hepatic fibrosis of Qi sta- ganation and blood stasis pattern. Method： All 45 patients were randomized into 17 cases in the treatment group, 16 cases in the control group and 12 cases in the blank group. The blank group received routine treatment of liver pro- tection; oral tiopronin tablets, each time 0.1g, three times per day, the treatment group took HuaQian BaoGan pre- scription （capsule）, four pills each time, three times per day; the control group took FuZheng HuaYu capsule, five pills each time, three times per day. Twelve weeks were one course of treatment. After one course of treatment, the changes of symptom scales before and after treating, liver fimction index, four indexes of hepatic fibrosis, genetic ex- pressions including transforming growth factorβ1 （TGF-β1）, platelet-derived growth factor （PDGF）, tumor necrosis factor α（TNF-α） were observed as well as the change of Fibroscan value was detected with instant detector. Result： The treatment group was obviously superior to the blank group in improving the symptoms of patients suffering from hepatic fibrosis, liver function recovery, decreasing four indexes of hepatic fibrosis, inhibiting genetic expressions in- cluding TGF-β1, PDGF, TNF-α and others, lowering Fibroscan value （P〈0.05）, the difference had no statistical meaning compared with the control group（P〉 0.05）, but obviously better than the blank group. Conclusion： HuaQian BaoGart prescription shows better effects against hepatic fibrosis.